Literature DB >> 18363543

The hepatic safety profile of duloxetine: a review.

Roger S McIntyre1, Zilomi D Panjwani, Ha T Nguyen, Hanna O Woldeyohannes, Mohammad Alsuwaidan, Joanna K Soczynska, Maria T Lourenco, Jakub Z Konarski, Sidney H Kennedy.   

Abstract

BACKGROUND: Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert.
OBJECTIVE: To characterize the hepatic safety profile of duloxetine.
METHODS: We conducted a PubMed search of all English-language articles published between January 1990 and December 2007 and contacted the manufacturer (Eli Lilly, Inc.).
RESULTS: Elevations of alanine aminotransferase to three times the upper limit of normal occurs in 0.9-1.7% of duloxetine-treated patients versus 0.0-0.3% of placebo-treated patients. Hepatocellular, cholestatic and mixed hepatocellular-cholestatic forms of hepatic injury have been described.
CONCLUSION: Duloxetine does not appear to pose a greater hazard for hepatic toxicity when compared to other conventional antidepressants. Systematic monitoring of liver aminotransferases does not appear to be warranted with routine duloxetine use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363543     DOI: 10.1517/17425255.4.3.281

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  11 in total

Review 1.  Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease.

Authors:  Karen E Stewart; James L Levenson
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

Review 2.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

Review 3.  Translational investigation and treatment of neuropathic pain.

Authors:  Bo Xu; Giannina Descalzi; Hai-Rong Ye; Min Zhuo; Ying-Wei Wang
Journal:  Mol Pain       Date:  2012-03-09       Impact factor: 3.395

4.  Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder.

Authors:  Young-Min Park; Bun-Hee Lee; Heon-Jeong Lee; Seung-Gul Kang
Journal:  Psychiatry Investig       Date:  2010-08-30       Impact factor: 2.505

Review 5.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

6.  Duloxetine-induced liver injury in patients with major depressive disorder.

Authors:  Seung-Gul Kang; Young-Min Park; Heon-Jeong Lee; Byungmun Yoon
Journal:  Psychiatry Investig       Date:  2011-08-10       Impact factor: 2.505

7.  A systematic review of agomelatine-induced liver injury.

Authors:  Silka Dawn Freiesleben; Karolina Furczyk
Journal:  J Mol Psychiatry       Date:  2015-04-21

8.  Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents.

Authors:  Woojin Kim; Yeongu Chung; Seunghwan Choi; Byung-Il Min; Sun Kwang Kim
Journal:  Int J Mol Sci       Date:  2017-12-05       Impact factor: 5.923

9.  Hepatocellular carcinoma and antidepressants: a nationwide population-based study.

Authors:  Vincent Chin-Hung Chen; Chiao-Fan Lin; Yi-Hsuan Hsieh; Hsin-Yi Liang; Kuo-You Huang; Wei-Che Chiu; Yena Lee; Roger S McIntyre; Hsiang-Lin Chan
Journal:  Oncotarget       Date:  2017-05-02

Review 10.  Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Authors:  Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.